Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis

Du, Xiaobo; Lang, Jinyi; Xu, Jing; Lü, You; Wang, Yuming; Zhao, Jingxia; Diao, Peng; Yuan, Zhiping; Yao, Bin; Fan, Ling-yu; Wang, Guoqing; Liu, Li; Ding, Zhenyu; Wang, Yongsheng; Li, Tao; Wang, Rui; Mao, Yun-Qiu; Kan, Bin; Wu, H. C.; Yang, Hansuo; Wu, Hongbo; Wei, Yuquan; Zhao, Xia

doi:10.1007/s10495-008-0253-2

Cited by 14 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3A and p < 0.05). Consistent with the data of tumor volume, the mean weight of tumors of mice treated with Plk1 shRNA lipoplex was 0.04 ± 0.01 g, accounting for 13.98% of that of mice treated with 5% glucose (0.31 ± 0.10 g) and 22.85% of mice treated with HK-shRNA lipoplex (0.19 ± 0.04 g) ( Fig. 3B and p < 0.05).…”

Section: Intravenous Liposomal Delivery Of the Short Hairpin Rnas Agasupporting

confidence: 88%

Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma

Deng¹,

Jiang²,

Yang³

et al. 2011

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

Section: Intravenous Liposomal Delivery Of the Short Hairpin Rnas Agasupporting

confidence: 88%

Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma

Deng¹,

Jiang²,

Yang³

et al. 2011

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

“…Flow cytometric analysis was performed as previously reported (26,27). Cells (∼2x10 5 cells/well) were plated in 6-well plates and treated with NS, Lip-null (2 μg pVAX/6 μg liposome mixtures), Lip-phTERT-M (2 μg phTERTP-M/6 μg lipo-some mixtures), Lip-pVAX-M (2 μg pVAX-M/6 μg liposome mixtures) or etoposide (0.1 μg/ml).…”

Section: Methodsmentioning

confidence: 99%

Gene therapy using the human telomerase catalytic subunit gene promoter enables targeting of the therapeutic effects of vesicular stomatitis virus matrix protein against human lung adenocarcinoma

Zhang

Tan

Yang

et al. 2012

Experimental and Therapeutic Medicine

Self Cite

View full text Add to dashboard Cite

The catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT), is highly active in immortalized cells and more than 90% of human cancer cells, but is quiescent in the majority of normal somatic cells. Thus, the hTERT promoter has been extensively used in targeted cancer gene therapy. Vesicular stomatitis virus (VSV) matrix protein (MP) induces the apoptosis of tumor cells in the absence of other viral components. In our previous studies, we successfully constructed the pVAX-M plasmid from the pVAX plasmid, which expressed wild-type VSV MP (VSV MP is under the control of the CMV promoter) and demonstrated that pVAX-M efficiently suppresses the growth of malignant tumors via the induction of apoptosis in vitro and in vivo. The present study was designed to construct the plasmid phTERTM (VSV MP is under the control of the hTERT promoter) and investigate whether it had a targeted antitumor effect in nude mice bearing human lung adenocarcinoma. In vitro, A549 human lung adenocarcinoma cells were treated with NS, Lip-null, etoposide, Lip-pVAX-M or Lip-phTERT-M, and examined for cell viability through MTT assays or for apoptosis by flow cytometry and TUNEL assays. In vivo, A549 human lung carcinoma models in nude mice were established. Mice were treated with 10 4-weekly intravenous administrations of NS, Lip-null, etoposide (2 mg/kg), Lip-pVAX-M or Lip-phTERT-M. Subsequently, Lip-phTERT-M was found to be the most efficient inhibitor of tumor growth and inducer of tumor cell apoptosis when compared with the other groups in vivo and in vitro (P<0.05). Notably, immunohistochemical staining showed that Lip-phTERT-M significantly limited the overexpression of VSV MP to the tumor tissues and reduced VSV MP expression in other organs in comparison with Lip-pVAX-M (P<0.05). Therefore, it can be concluded that phTERT-M demonstrates a targeted antitumor effect on A549 human lung adenocarcinoma cells. These observations suggest that phTERT-M gene therapy may be a novel and potent strategy for targeting human lung adenocarcinoma.

show abstract

“…10, 37 The cell apoptosis inducing and anti-proliferation capacity of VSVMP gene have been well characterized, demonstrating strong potential in cancer gene therapy. In our study, the anti-cancer properties of VSVMP gene in plasmid and mRNA form were compared.…”

Section: 41mentioning

confidence: 99%

Delivery of modified mRNA encoding vesicular stomatitis virus matrix protein for colon cancer gene therapy

Men

Zhang

et al. 2018

RSC Adv.

View full text Add to dashboard Cite

Plasmid DNA based gene delivery has been widely utilized among both pre-clinical and clinical gene therapy studies. However, therapeutic efficiency is usually limited by the size and potential immunestimulation issue of plasmid backbone. As an alternative form of genetic material, chemically modified messenger RNA (mRNA) provides a promising alternative to plasmid DNA. In this work, an in vitro transcription mRNA encoding vesicular stomatitis virus matrix protein (VSVMP) was delivered by a cationic liposome-protamine complex, resulting in high mRNA transporting and expression efficiency.The liposome-protamine complex delivered VSVMP mRNA strongly inhibits the growth of C26 tumor cells through inducing apoptosis, while obvious tumor regressions were achieved on both abdominal cavity metastatic and subcutaneous xenograft models in vivo with high safety. Our results also demonstrated that the liposome-protamine-mRNA complex was as potent as its plasmid DNA counterpart, showing strong potential in further colon cancer therapy.

show abstract

Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis

Cited by 14 publications

References 35 publications

Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma

Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma

Gene therapy using the human telomerase catalytic subunit gene promoter enables targeting of the therapeutic effects of vesicular stomatitis virus matrix protein against human lung adenocarcinoma

Delivery of modified mRNA encoding vesicular stomatitis virus matrix protein for colon cancer gene therapy

Contact Info

Product

Resources

About